Showing results (341-350 of 377) with videos related to

Sort By:
Pageof 38
Journal of Neurotrauma|December 7, 2018
Paths to Successful Translation of New Therapies for Severe Traumatic Brain Injury in the Golden Age of Traumatic Brain Injury Research: A Pittsburgh VisionPatrick M Kochanek, Travis C Jackson, Ruchira M Jha, et al.
Heart Rhythm|February 7, 2025
Reassessing the need for primary prevention implantable cardioverter-defibrillators in contemporary patients with heart failureIlan Goldenberg, Justin Ezekowitz, Christine Albert, et al.
Journal of Cardiac Failure|February 6, 2025
Reassessing the need for primary prevention implantable cardioverter-defibrillators in contemporary patients with heart failureIlan Goldenberg, Justin Ezekowitz, Christine Albert, et al.
Intensive Care Medicine|August 21, 2013
Harmonizing international trials of early goal-directed resuscitation for severe sepsis and septic shock: methodology of ProCESS, ARISE, and ProMISe, David T Huang, Derek C Angus, et al.
JAMA|May 20, 2019
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for SepsisChristopher W Seymour, Jason N Kennedy, Shu Wang, et al.
Open Forum Infectious Diseases|July 12, 2021
Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 InfectionJ Ryan Bariola, Erin K McCreary, Richard J Wadas, et al.
The New England Journal of Medicine|March 22, 2017
Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis, Kathryn M Rowan, Derek C Angus, et al.
Journal of the American College of Cardiology|August 4, 2018
Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID TrialWojciech Zareba, James P Daubert, Christopher A Beck, et al.
Contemporary Clinical Trials|December 13, 2021
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 daysErin K McCreary, J Ryan Bariola, Tami Minnier, et al.
JAMA Network Open|April 12, 2022
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19Erin K McCreary, J Ryan Bariola, Richard J Wadas, et al.
Pageof 38